ACTOS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Actos, and when can generic versions of Actos launch?
Actos is a drug marketed by Takeda Pharms Usa and is included in one NDA.
The generic ingredient in ACTOS is pioglitazone hydrochloride. There are twenty-seven drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the pioglitazone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Actos
A generic version of ACTOS was approved as pioglitazone hydrochloride by CHARTWELL RX on October 26th, 2012.
Summary for ACTOS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 145 |
Patent Applications: | 3,944 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ACTOS |
Drug Sales Revenues: | Drug sales revenues for ACTOS |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ACTOS |
What excipients (inactive ingredients) are in ACTOS? | ACTOS excipients list |
DailyMed Link: | ACTOS at DailyMed |
US Patents and Regulatory Information for ACTOS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-001 | Jul 15, 1999 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-002 | Jul 15, 1999 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-003 | Jul 15, 1999 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ACTOS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-002 | Jul 15, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-002 | Jul 15, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-001 | Jul 15, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-001 | Jul 15, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-001 | Jul 15, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ACTOS
See the table below for patents covering ACTOS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Argentina | 240698 | PROCEDIMIENTO PARA PREPARAR COMPUESTOS DE 5-(4-(2-(5-ETIL-2-PIRIDIL)-ETOXI)BENZIL)-2,4-TIAZOLIDINDIONA Y SUS SALES (PROCESS FOR THE PREPARATION OF 5-(4-(2-(5-ETHYL-2-PYRIDIL)-ETHOXY)BENZYL)-2,4-THIAZOLODINEDIONE AND THEIR SALTS) | ⤷ Try a Trial |
Finland | 860232 | ⤷ Try a Trial | |
Slovakia | 287351 | ⤷ Try a Trial | |
South Korea | 920010046 | ⤷ Try a Trial | |
Austria | 438397 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ACTOS
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1174135 | SPC/GB10/011 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: THE COMBINATION OF PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY THE HYDROCHLORIDE SALT, AND GLIMEPIRIDE.; REGISTERED: UK EU/1/06/366/001 20070108; UK EU/1/06/366/002 20070108; UK EU/1/06/366/003 20070108; UK EU/1/06/366/004 20070108; UK EU/1/06/366/005 20070108; UK EU/1/06/366/006 20070108; UK EU/1/06/366/019 20070108; UK EU/1/06/366/020 20070108; UK EU/1/06/366/021 20070108; UK EU/1/06/366/022 20070108; UK EU/1/06/366/013 20070108; UK EU/1/06/366/014 20070108; UK EU/1/06/366/015 20070108; UK EU/1/06/366/016 20070108; UK EU/1/06/366/017 20070108; UK EU/1/06/366/018 20070108; UK EU/1/06/366/007 20070108; UK EU/1/06/366/008 20070108; UK EU |
0861666 | C00861666/01 | Switzerland | ⤷ Try a Trial | FORMER REPRESENTATIVE: BOHEST AG, CH |
1174135 | 91606 | Luxembourg | ⤷ Try a Trial | 91606, EXPIRES: 20210620 |
1174135 | 437 | Finland | ⤷ Try a Trial | |
1174135 | CA 2009 00045 | Denmark | ⤷ Try a Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |